Back to Archived Journals » Research and Reports in Transdermal Drug Delivery » Volume 2
The status of rotigotine as a safe and effective alternative in the treatment of restless legs syndrome
Authors Bourgeois P, Frenette E
Received 15 December 2012
Accepted for publication 4 February 2013
Published 8 April 2013 Volume 2013:2 Pages 1—8
DOI https://doi.org/10.2147/RRTD.S30575
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 3
Pascale Bourgeois, Eric Frenette
CHUS a/s Service de Neurologie, Sherbrooke, QC, Canada
Abstract: Restless legs syndrome (RLS) is characterized by an urge to move the legs that occurs mainly with inactivity, and it is relieved by movement and is usually worse by the end of the day. It is highly prevalent, affecting 1.9% to 4.5% of the population, and although its etiology is uncertain, genetic factors seem to be involved. When symptoms are severe enough to warrant chronic therapy, dopamine receptor agonists are to be considered for initial treatment. Rotigotine, the most recently developed drug in this category, is the only one available for transdermal delivery in RLS. It was initially designed for the treatment of Parkinson’s disease. The US Food and Drug Administration approved its use in cases of moderate to severe RLS in April 2012. Its efficacy has been well established in randomized placebo-controlled trials, as it appears to be especially useful in patients with daily symptoms. The most commonly reported side effect is local skin reaction. Complications such as augmentation, somnolence, or compulsive behavior may happen, although they seldom occur. The American Academy of Sleep Medicine clinical practice guideline recommends a “Guideline Level” for rotigotine, and European RLS guidelines provide a “level A” recommendation for short-term therapy; it also was the only dopaminergic agonist considered to be effective for the long-term management of RLS.
Keywords: restless legs syndrome, 2-rotigotine, dopamine receptor agonist
© 2013 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.